Investors can expect a company’s stock to rise or fall based on the buying and selling of stock by its insiders. Cytokinetics Inc shares valued at $395,554 were sold by Malik Fady Ibraham on Oct 15 ’24. At $54.19 per share, Malik Fady Ibraham sold 7,300 shares. The insider’s holdings dropped to 116,920 shares worth approximately $6.38 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, FADY MALIK purchased 7,300 shares, netting a total of over 395,578 in proceeds.
Before that, Blum Robert I had sold 5,000 shares from its account. In a trade valued at $278,050, the President & CEO traded Cytokinetics Inc shares for $55.61 each. Upon closing the transaction, the insider’s holdings decreased to 5,000 shares, worth approximately $21.67 million.
As published in a research note from Goldman on August 13, 2024, Cytokinetics Inc [CYTK] has been rated down from a Buy to a Neutral and the price target has been revised to $60 from $85. Analysts at UBS downgraded the stock from ‘”a Buy”‘ to ‘”a Neutral”‘ outlook in a report released in late January. As of January 05, 2024, Morgan Stanley has decreased its “an Overweight” rating to a “an Equal-weight” for CYTK. Earlier on November 09, 2023, Goldman initiated its rating. Their recommendation was “a Buy” for CYTK stock.
Analyzing CYTK Stock Performance
During the last five days, there has been a surge of approximately 2.60%. Over the course of the year, Cytokinetics Inc shares have dropped approximately -34.69%. Shares of the company reached a 52-week high of $110.25 on 01/08/24 and a 52-week low of $46.25 on 05/28/24. A 50-day SMA is recorded $55.08, while a 200-day SMA reached $63.57. Nevertheless, trading volume fell to 0.91 million shares from 0.81 million shares the previous day.
Support And Resistance Levels for Cytokinetics Inc (CYTK)
According to the 24-hour chart, there is a support level at 54.03, which, if violated, would cause prices to drop to 53.54. In the upper region, resistance lies at 55.18. The next price resistance is at 55.83. RSI (Relative Strength Index) is 49.72 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.61, which suggests the price will decrease in the coming days. Percent R is at 45.59%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
